March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes. The findings were presented in a late-breaking session at ACC.26 in New Orleans.

heart failure, blood monitor, wearables

Four vital signs make up the traditional core of clinical diagnosis: heart rate, blood pressure, respiratory rate and temperature. Over the years, hundreds of years, these metrics have remained largely unchanged while technology and medical innovation have advanced rapidly.

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The launch follows US Food and Drug Administration (FDA) 510(k) clearance for the system.

April 2, 2026 — Omron Healthcare Co. has launched a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance research through community-based innovation in cardiovascular care.

March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension . 

March 31, 2026 — The global community of heart rhythm specialists will unite in Paris, April 12-14, 2026, for EHRA 2026, the annual congress of the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC).

March 30, 2026 — At ACC.26 in New Orleans, Esperion presented  two post-hoc analyses from CLEAR Outcomes focused on risk of ischemic stroke and risk of major adverse cardiovascular events (MACE) in patients with autoimmune or inflammatory diseases. These data were presented as moderated poster presentations.

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it could be a heart attack. She was 36, a new mom, and otherwise healthy.

At the hospital, blood tests showed signs of a heart attack, but her arteries appeared normal.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now